A non-hormonal male contraceptive is a contraceptive that does not involve the administration of hormones or hormone blockers.
This review will focus on the use of lonidamine derivatives and inhibitors of retinoic acid biosynthesis and function as approaches to male non-hormonal contraception. Two current lonidamine derivatives, adjudin and H2-gamendazole, are in development as male contraceptives. These potent anti-spermatogenic compounds impair the integrity of the apical ectoplasmic specialization, resulting in premature spermiation and infertility. Another approach to male contraceptive development is the inhibition of retinoic acid in the testes, as retinoic acid signaling is necessary for spermatogenesis. The administration of the retinoic acid receptor antagonist BMS-189453 reversibly inhibits spermatogenesis in mice. Similarly, oral dosing of WIN 18,446, which inhibits testicular retinoic acid biosynthesis, effectively contracepts rabbits. Hopefully, one of these approaches to non-hormonal male contraception will prove to be safe and effective in future clinical trials.
Written by:
Nya-Ngatchou JJ, Amory JK. Are you the author?
Departments of Medicine, Center for Research in Reproduction and Contraception, University of Washington, Seattle, WA 98195, USA.
Reference: Contraception. 2013 Mar;87(3):296-9.
doi: 10.1016/j.contraception.2012.08.016
PubMed Abstract
PMID: 22995542
UroToday.com Male Infertility & Reproduction Section
